Free Trial
NASDAQ:HUMA

Humacyte Q1 2025 Earnings Report

Humacyte logo
$1.32 +0.13 (+10.92%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$1.32 0.00 (0.00%)
As of 05:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Upcoming Event
Earnings Conference Call
Humacyte Q1 2025
00:00 / 00:00
Live Transcript
Follow Audio

Humacyte EPS Results

Actual EPS
N/A
Consensus EPS
-$0.19
Beat/Miss
N/A
One Year Ago EPS
N/A

Humacyte Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.46 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Humacyte Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Humacyte Earnings Headlines

Humacyte Q1 2025 Earnings Preview
Exploring Humacyte's Earnings Expectations
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Humacyte Insiders Placed Bullish Bets Worth US$949.4k
See More Humacyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Humacyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Humacyte and other key companies, straight to your email.

About Humacyte

Humacyte (NASDAQ:HUMA) engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

View Humacyte Profile

More Earnings Resources from MarketBeat